Cancer represents a key challenge in medical science, manifesting as a disease where the immune system fails to recognize and eliminate tumor cells. The phenomenon of immune evasion by cancer cells ...
Researchers have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO. Their study shows that blocking MARCO in ...
The field of cancer immunotherapy has achieved remarkable progress, introducing strategies such as immune checkpoint inhibitors and adoptive cell therapies ...
About 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven Center for Cancer Biology) discovered that an enzyme called HPGDS (expressed in ...
A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators reveals how melanoma, the deadliest form of skin cancer, evolves to resist immunotherapy and identifies a potential ...
Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse events.
A Bristol Myers Squibb immunotherapy currently approved as a first-line treatment for metastatic melanoma has failed a pivotal clinical trial intended to support expanding the therapy’s use to keeping ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback